# Quetiapine

## Quelip XR 200mg

| 藥物代碼 | OQUEP |
| :--- | :--- |
| 適應症 | Schizophrenia. Schizophrenia, Maintenance. Bipolar disorder, depressed phase, Acute management, monotherapy. Bipolar I disorder, Acute management, in combination with lithium or divalproex. Bipolar I disorder, Acute management, monotherapy. Bipolar I disorder, Maintenance, in combination with lithium or divalproex. Major depressive disorder. |
| 副作用 | CommonCardiovascular: Increased diastolic arterial pressure \(Pediatric, 40.6% \), Increased systolic arterial pressure \(Pediatric, 15.2% \), Orthostatic hypotension \(Up to 7% \), Tachycardia \(Up to 6% \)Endocrine metabolic: Serum cholesterol raised \(7% to 18% \), Serum triglycerides raised \(8% to 28% \), Weight gain \(3% to 28% \)Gastrointestinal: Abdominal pain \(3% to 7% \), Constipation \(2% to 11% \), Increased appetite \(2% to 12% \), Indigestion \(2% to 7% \), Nausea \(Pediatric, 6% to 10% \), Vomiting \(Pediatric, 7% to 8% \), Xerostomia \(Adult, 9% to 44%; pediatric, 4% to 10% \)Hepatic: Increased liver enzymes \(1% to 6% \)Musculoskeletal: Backache \(3% to 5% \)Neurologic: Asthenia \(Up to 10% \), Dizziness \(8% to 19% \), Extrapyramidal disease \(1.1% to 12.9% \), Headache \(17% to 21% \), Insomnia \(8% to 12% \), Lethargy \(1% to 5% \), Somnolence \(18% to 57% \), Tremor \(2% to 8% \)Psychiatric: Agitation \(6% to 20% \)Respiratory: Nasal congestion \(3% to 5% \), Pharyngitis \(4% to 6% \)Other: Fatigue \(3% to 14% \), Pain \(7% \)SeriousCardiovascular: Prolonged QT interval \(0.1% to less than 1% \), Sudden cardiac death, Syncope \(0.3% to 2% \)Endocrine metabolic: Diabetic ketoacidosisGastrointestinal: Bowel obstruction, PancreatitisHematologic: Agranulocytosis, Leukopenia, Neutropenia \(0.3% to 1.5% \)Immunologic: AnaphylaxisNeurologic: Seizure \(0.05% to 0.5% \), Tardive dyskinesiaPsychiatric: Suicidal thoughtsReproductive: PriapismOther: Neuroleptic malignant syndrome |
| 禁忌 | Hypersensitivity to quetiapine or any component of the product. Anaphylactic reactions have been reported. |
| 藥物保存方式 | 30℃以下 |
| 用法用量 | Schizophrenia \(Acute\): 300 mg orally in the evening on day 1 and titrate to usual maintenance dose between 400 to 800 mg once daily; dose increases may occur at intervals of at least 1 day in increments of up to 300 mg/day; MAX dose 800 mg/day The safety of doses above 800 mg/day has not been evaluated in clinical trials. Bipolar disorder, depressed phase, Acute management, monotherapy: 50 mg orally once daily on day 1; 100 mg once daily on day 2; 200 mg once daily on day 3; and then 300 mg once daily on day 4, with doses given in the evening; usual and MAX dose is 300 mg/day Bipolar I disorder, Acute management, in combination with lithium or divalproex: 300 mg orally in the evening on day 1; 600 mg in the evening on day 2; with further dosage adjustment to usual maintenance dose between 400 and 800 mg once daily beginning on day 3, depending on patient response and tolerance; MAX dose 800 mg/day Major depressive disorder, Monotherapy: Initial, 50 mg orally once daily on days 1 and 2, 150 mg once daily on days 3 and 4, and 300 mg once daily thereafter, with discontinuation of previous antidepressant complete by day 7; may extend titration period to include 3 additional days, and reach 300 mg/day by day 8 and reduce to 150 to 200 mg/day for intolerance. |
| 肝功能異常 | 需 調 整 劑 量  Hepatic impairment: Initial dose, 50 mg/day; increase in increments of 50 mg/day depending on patient response and tolerance.\[Micromedex:2020.06.24\] |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Compatible - maternal benefit &gt;&gt; embryo-fetal risk |
| 附帶說明 | \[仿單\]目前對於 Quetiapine XR 使用於孕婦，還沒有適當且控制良好的研究。 在有限的出版文獻中，沒有重大畸形與懷孕期間暴露於 quetiapine 有關。 在追蹤一些於孕期使用 qutiapine 的病人後，有出現新生兒戒斷症候群的案例。 在動物試驗發生過胚胎-胎兒毒性。 只有在治療效益大於潛在危險時方可在懷孕期間使用Quetiapine XR。 關於在懷孕期間使用 quetiapine 治療思覺失調症及其他精神疾病的出版資料有限。 在一項前瞻性觀察研究中，21 名在懷孕期間暴露於 quetiapine 及其他精神活性藥物的婦女生出的嬰兒沒有重大畸形。 在42 名由懷孕期間使用 quetiapine 的婦女所生出的嬰兒中，沒有重大畸形報告\(一項研究有 36 名婦女，6 個病例報告\)。 由於懷孕期間暴露於本藥的人數有限，這些上市後的資料並不能可靠的估計頻率或沒有不良結果。 當懷孕的大鼠與兔子在器官發生期暴露於quetiapine，在高達治療思覺失調症的人類最高建議劑量 2.4倍的劑量下\(MRHD，依 mg/m2 計算，每天 800 mg\)，胎兒重大畸形的發生率並未增加；然而確實有胚胎/胎兒毒性的證據。 胎兒骨骼骨化延遲發生在接受人類最高劑量的 0.6 至 2.4 倍劑量的大鼠，以及接受人類最高劑量的 1.2 至 2.4 倍劑量的兔子。 在人類最高劑量的 2.4 倍劑量下，兔子胎兒的腕/跗彎曲\(輕微軟組織異常\)發生率增加，這兩種動物均有胎兒體重減輕的現象。 母體毒性\(即體重增加減少及/或死亡\)發生在接受人類最高劑量的 2.4 倍劑量的大鼠，以及接受人類最高劑量的 0.6 至 2.4 倍劑量\(所有的劑量\)的兔子。 在一項大鼠周產期/產後生殖研究中，在接受人類最高劑量的 0.01、0.12 及 0.24 倍劑量治療的懷孕婦女並未觀察到與藥物有關的影響。然而，在一項初步周產期/產後生殖研究中，在人類最高劑量的 3.0倍的劑量下，有胎兒和仔鼠死亡增加，平均窩重減輕的現象。 |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | \[仿單\]Quetiapine XR 會分泌到人類乳汁中。將 Quetiapine XR 投予授乳婦時應小心。 在出版的病例報告中，quetiapine 在乳汁中的濃度從可檢測程度到 170 μg/L。 估計的嬰兒劑量是經體重校正的母親劑量的0.09%至 0.43%。 根據有限的母親/嬰兒配對數\(N=8\)，算出嬰兒每日劑量從小於 0.01 mg/kg \(母親劑量高達每天 400 mg\)至 0.1 mg/kg \(母親劑量高達每天 400 mg\)。 |
| 注射劑給藥建議途徑 | AC, PC, PO, WM |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## Seroquel 25mg

| 藥物代碼 | OSER2 |
| :--- | :--- |
| 適應症 | Schizophrenia, manic episodes associated with bipolar disorder. |
| 副作用 | Dry mouth, somnolence, dizziness , & dyspepsia. Heart rate increased, hypotension, weight increased, tremor, akathisia, increased appetite, blurred vision, postural dizziness, pyrexia, dysarthria, dystonia, drooling, syncope, tardive dyskinesia, dysphagia, leukopenia & rash. Anaphylactic reaction, peripheral edema, rhinitis, eosinophilia, hypersensitivity, elevations in γ- GT levels & restless legs syndrome have also been reported.Cardiovascular: Hypertension \(1% to 2% \(adults\); 15.2 to 40.6% \(children and adolescents\) \), Orthostatic hypotension \(4% to 7% \(adults\); less than 1% \(children and adolescents\) \), Tachycardia \(0.5% to 7% \)Endocrine metabolic: Serum cholesterol raised \(7% to 18% \), Serum triglycerides raised \(8% to 22% \), Weight gain \(3% to 23% \)Gastrointestinal: Abdominal pain \(4% to 7% \), Constipation \(2% to 11% \), Increased appetite \(2% to 12% \), Indigestion \(2% to 7% \), Vomiting \(1% to 11% \), Xerostomia \(4.1% to 44% \)Hepatic: Increased liver enzymes \(1% to 6% \)Musculoskeletal: Backache \(3% to 5% \)Neurologic: Asthenia \(2% to 10% \), Dizziness \(9% to 18% \), Extrapyramidal disease \(3% to 12.9% \), Headache \(7.4% to 21% \), Insomnia \(8% to 12% \), Lethargy \(1% to 5% \), Somnolence \(16% to 57% \), Tremor \(2% to 8% \)Psychiatric: Agitation \(6% to 20% \)Respiratory: Nasal congestion \(3% to 5% \), Pharyngitis \(4% to 6% \)Other: Fatigue \(3% to 14% \), Pain \(1% to 7% \) |
| 禁忌 | NA |
| 藥物保存方式 | 室溫 |
| 用法用量 | Schizophrenia Total daily dose: 50 mg \(Day 1\), 100 mg \(Day 2\), 200 mg \(Day 3\), 300 mg \(Day 4\). From Day 4 onwards, dose titrated to dose range of 300-450 mg/day. Dose may be adjusted within the range 150-750 mg/day. Manic episodes associated with bipolar disorder As monotherapy of as adjunct therapy to mood stabilizers, total daily dose: 100 mg \(Day 1\), 200 mg \(Day 2\), 300 mg \(Day 3\), 400 mg \(Day 4\). Further dosage adjustments up to 800 mg/day by Day 6 should be in increments of no &gt; 200 mg/day. Adjust dose within the range of 200-800 mg/day depending on clinical response & tolerability of the patient. Usual effective dose range: 400-800 mg/day. |
| 肝功能異常 | 需 調 整 劑 量  肝功能不全患者建議起始劑量為 25 mg/day, increase dose daily in increments of 25 to 50 mg/day to an effective dose based on response and tolerability |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Compatible - maternal benefit &gt;&gt; embryo-fetal risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

